ReviewImmuno-oncology technology2025
Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy.
Review in Immuno-oncology technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision-Making, a Review.Head & neck · 2026Review
- Therapeutic vaccines targeting solid tumors: A series of clinical trial analysis over the past decade.Translational oncology · 2026Review
- Peripheral T-Cell Receptor β Repertoire Dynamics Correlate with Response to Anti-PD-L1 Therapy in Non-Small Cell Lung Cancer.Cancers · 2026Article
- Modeling TCR-Epitope Recognition Specificity: What We Should Learn to Succeed.Immunological reviews · 2026Review
- Reprogramming the tumor immune microenvironment in cervical cancer: synergy between radiotherapy and immunotherapy.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The T-cell receptor (TCR) repertoire, representing the vast diversity of T cells, is a cornerstone of adaptive immunity and a powerful tool in oncology. Advances in high-throughput sequencing have enabled deep profiling of TCR diversity and clonality, highlighting the repertoire as a promising biomarker for cancer diagnosis, prognosis and therapeutic monitoring. This review synthesizes the current understanding of TCR repertoire analysis in cancer care. Distinct TCR features in tumors and peripheral blood can differentiate cancer patients from healthy individuals and help stage disease. Prognostically, a focused, clonal intratumoral repertoire is often associated with improved survival, whereas high diversity in peripheral blood typically reflects robust immune competence and better outcomes. In cancer immunotherapy, TCR profiling offers predictive insights; high baseline tumor clonality frequently correlates with response to anti-programmed cell death protein 1/programmed death-ligand 1 inhibitors, while greater peripheral diversity may predict benefit from anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) therapy. Dynamic monitoring often shows an increase in clonality in patients responding to treatment. Furthermore, TCR analysis is integral to optimizing and tracking adoptive cell therapies and cancer vaccines. Despite this potential, significant challenges, including a lack of methodological standardization, currently limit widespread clinical application. Integrating TCR analysis with multi-omic and single-cell technologies is essential to overcoming these hurdles and advancing personalized immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.